-
- Company
Acquisition will advance company's cell culture portfolio with internationally recognized pioneer in organoid development.
Merck Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
– Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development
– HUB’s organoid offering complements company’s cell culture portfolio of media, reagents, and benchtop instrumentation
– Organoids provide drug response data earlier in the development pr…